Prognostic Value of Liver Biomarkers in Hepatocellular Carcinoma Patients Undergoing Yttrium 90 Transarterial Radioembolization (TARE): A Retrospective Pilot Study

肝细胞癌 医学 回顾性队列研究 经动脉栓塞 放射科 核医学 内科学 肿瘤科 栓塞
作者
María del Pilar Bayona Molano,M. Kolber,Juana V. Barrera,Muhammad R Akram,Mhd Wisam Alnablsi,Tanya Pothini,Riad Salem,Amit G. Singal
出处
期刊:Cureus [Cureus, Inc.]
标识
DOI:10.7759/cureus.61904
摘要

Introduction: Hepatocellular carcinoma (HCC) is a common cause of cancer-related death worldwide. The prognosis for HCC depends on the tumor stage, and curative therapies are more accessible in the early stages. However, effective treatments are available even in advanced stages. Transarterial radioembolization (TARE) is an alternative to transarterial chemoembolization (TACE) with reduced risk and extended disease progression time. Identifying prognostic indicators and treatment response biomarkers remains crucial. The purpose of this study was to assess the association between biomarkers related to fibrosis, liver function, and immune inflammation with tumor response to yttrium 90 transarterial radiotherapy (Y90 or TARE) in patients with HCC. Methods: This study enrolled patients who underwent Y90 radiotherapy for bridging, downstaging, or palliative treatment after discussion in a multidisciplinary tumor board. Using the modified Response Evaluation Criteria in Solid Tumors (mRECIST), tumor response was classified into two groups: "responders" (complete and partial response) and "non-responders" (stable and progressive disease). Logistic regression analysis was used to evaluate the association between predictors, biomarkers such as aspartate aminotransferase (AST)-to-platelet ratio index (APRI), fibrosis-4 (FIB-4), albumin-bilirubin (ALBI) score, model for end-stage liver disease (MELD) score, MELD sodium, and the systemic immune-inflammatory indexes, at established cut-offs and tumor response. Results: Of 35 patients, 22 (63%) were Whites and non-Hispanics, 32 (91%) were diagnosed with cirrhosis, and 14 (40%) of these had a viral etiology. According to mRECIST, 18 (51%) patients were classified as "responders." In multivariable logistic regression analysis, biomarkers associated with tumor response were ALBI score ≤-2.8 (odds ratio (OR) 6.1, 95%CI 2.7-14.4) and the neutrophil-to-lymphocyte ratio (NLR) ≤ 1.92 (OR 5.1, 95%CI 0.8-11.9). Biomarkers had moderate accuracy in predicting tumor response (C-statistic 0.75). Conclusion: The ALBI score is a reliable predictor of treatment response following TARE. The NLR index may offer further prognostic information, and both biomarkers can be used in combination; however, further research in larger sample sets is needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
英俊的铭应助研友_LkD29n采纳,获得10
刚刚
徐佳达完成签到,获得积分10
1秒前
shenxian82133发布了新的文献求助10
4秒前
李傲寒发布了新的文献求助10
5秒前
Man发布了新的文献求助10
5秒前
hyz完成签到,获得积分10
7秒前
8秒前
科研通AI5应助予安采纳,获得10
9秒前
科研x完成签到,获得积分10
9秒前
11秒前
听说外面下雨了完成签到,获得积分10
12秒前
CipherSage应助李傲寒采纳,获得10
13秒前
刘YF发布了新的文献求助10
17秒前
17秒前
orixero应助ty采纳,获得10
19秒前
20秒前
拉长的冷霜完成签到,获得积分10
20秒前
22秒前
英姑应助ccmaxp采纳,获得10
22秒前
wu先生完成签到,获得积分10
25秒前
jmn发布了新的文献求助10
25秒前
25秒前
29秒前
29秒前
30秒前
大米完成签到,获得积分10
30秒前
31秒前
31秒前
ty发布了新的文献求助10
33秒前
田様应助不安的小刺猬采纳,获得10
35秒前
damian完成签到,获得积分10
35秒前
JamesPei应助Fengh采纳,获得10
35秒前
WD发布了新的文献求助10
35秒前
善良天抒发布了新的文献求助10
36秒前
量子星尘发布了新的文献求助30
37秒前
37秒前
xiaojinyu发布了新的文献求助10
38秒前
zxh完成签到,获得积分10
38秒前
40秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975543
求助须知:如何正确求助?哪些是违规求助? 3519971
关于积分的说明 11200248
捐赠科研通 3256311
什么是DOI,文献DOI怎么找? 1798213
邀请新用户注册赠送积分活动 877446
科研通“疑难数据库(出版商)”最低求助积分说明 806338